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Tau protein aggregation is believed to be one of the key drivers of Alzheimer’s disease. 
The two hexapeptide amino acid sequences 306VQIVYK311, and 275VQIINK280 of the tau 
protein are responsible for aggregation, and subsequent functional loss leading to 
Alzheimer’s progression. Hence its important to understand the factors that promote the 
self-aggregation of this tau peptide fragments. Cellular microenvironmental polyanions 
are known to play a major role in tau protein aggregation and loss of function. Previous 
studies mainly focused on the effect of heparin and heparan sulfate solution on the full 
tau protein aggregation. Here we study the effect of cellular polyanion mimetics, 
glycosaminoglycans (GAGs) in solution and on surface to mimic intracellular and 
extracellular conditions, and cellular RNA on the aggregation of tau hexapeptide 
306VQIVYK311, and mutant tau peptide 273GKVQIIN_KLDL284 found frequently in 
taupathy. Characterization techniques used for the study include, biochemical assays, 
electron microscopy, and spectroscopy techniques to investigate the aggregation vitro. 
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Results show while all the GAGs in solution form play a role in tau peptides aggregation, 
heparin, chondroitin sulfate, and dermatan sulfate in particular significantly promote the 
tau peptides aggregation formation. On the other hand surface coated GAGs did not 
promote significant tau aggregation. As far as cellular RNA is concerned, results show 
significant increase in tau peptides aggregation and toxicity in neuroblastoma cells. The 
study on the tau peptides fragments aggregation in the presence of GAGs and cellular 
RNA, could provide novel information on the tau aggregation mechanism, and could 
open ways for developing cellular polyanions modulating therapeutics for treating 
Alzheimer’s disease. 
 





Tau protein aggregation and subsequent neurofibrillary tangle formation are major 
hallmarks of Alzheimer’s disease. Recent reports suggest understanding the tau 
aggregation mechanism could help develop clinically relevant therapies in combating the 
Alzheimer’s disease [1, 2]. Tau protein consists of 441 amino acids with microtubule 
binding region that contains four repeat peptide units [3, 4]. They are composed of 
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hexapeptide domains, which are believed to be the major drivers of tau pathological 
assembly. The hexapeptide repeats 306VQIVYK311, and 275VQIINK280, of the tau protein 
have been shown to form inter-tau beta sheets, aggregates, and fibril structures [5-9]. The 
hexapeptide repeats are well studied, and hence is widely used as a model to study tau 
aggregation in vitro.  
 
Several factors are known to influence the tau aggregation [5, 10-12]. Among them, 
polyanions, glycosaminoglycans (GAGs) and their sulfated forms, and cellular RNA have 
shown to induce Alzheimer’s like changes in tau protein and believed to play a major role 
in tau aggregation [13, 14]. Further, sulfated glycosaminoglycans have shown to promote 
tau aggregation and have been found to be present in Alzheimer’s disease affected brain 
[13, 15]. Hence it is important to understand the influence of the polyanions on tau 
aggregation. Previously, it has been shown that GAGs influence the aggregation of 
amyloid beta peptide (Aβ42) aggregation in vitro [16]. Also it has been reported that tau 
assemble into filaments like morphology in the presence of sulfated heparin [17], and 
heparin induced conformational changes in tau protein have been observed [18, 19]. 
Further, recently NMR studies on tau-glycans interactions have been reported, where it 
has been shown that 6-O-sulfation in heparin is important for tau interaction [20]. In 
another study, tau peptide fragments aggregation in the presence of heparin has been 
shown to shift the oligomeric conformation of tau and contribute to the subsequent fibril 
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formation kinetics and morphology of the final aggregates [21]. However, the effect of 
other glycosaminoglycan molecules on tau hexapeptides aggregation under intracellular 
and extracellular mimetic conditions hasn’t been explored in detail. In the extracellular 
conditions GAGS are displayed on the extracellular matrix surface, while in the 
intracellular conditions, they are present in the solution. Given that tau aggregation has 
been observed both in intra-cellular and extracellular microenvironment [22, 23], it is 
important to test the tau aggregation in the presence of GAGs both in solution and on 
surface. Further, effect of cellular RNA on the tau peptides aggregation is yet to be 
explored as well.  
 
Here in this paper we study the effect of GAG molecules heparin (Hep), heparan sulfate 
(HepS), dermatan sulfate (DS), chondroitin sulfate (CS), and hyaluronic acid (HA) in 
solution and on surface, and cellular RNA, on the aggregation of tau hexapeptide domain 
306 VQIVYK311 (Tau V) segment from the microtubule binding region of tau protein, and 
the ΔK280 mutant peptide fragment 273GKVQIIN_KLDL284(Tau N) widely found in 
taupathy. The aggregation of the peptides in the presence of polyanions was studied 
utilizing the biochemical, microscopy, and spectroscopy characterization methods, 
thioflavin S fluorescence assay, transmission electron microscopy (TEM), atomic force 
microscopy (AFM), turbidity, dynamic light scattering (DLS), and cell toxicity assay. 
The results show that the heparin, chondroitin sulfate, and dermatan sulfate in solution, 
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significantly promote tau peptides aggregation and fibril formation, while surface coated 
GAGs did not promote significant aggregation. Further, cellular RNA significantly 
promoted the peptides aggregation as well. The study demonstrates for the first time the 
effect of cellular polyanion mimetics on tau peptides aggregation, and hence could 
provide added information on the role of polyanions in tau aggregation. 
 
2. Materials and Methods 
 
Materials 
Tau peptides (Ac-VQIVYK-NH2, Ac-GKVQIINKLDL-NH2 were custom synthesized 
from Genscript. Low molecular weight heparin, heparan sulfate (GAG-HS01), dermatan 
sulfate (GAG-DS01), and hylaluronic acid (HA93), were purchased from Galen 
Laboratory Supplies. Chondroitin sulfate (C4384), all other chemicals, and reagents were 
purchased from Sigma Aldrich. Heparin/GAG binding plates (SKU : H/G plates) was 
purchased from Galen Laboratory Supplies,  and the PureLink RNA mini kit was 
purchased from Thermo Fisher Scientific. 
 
ThS fluorescence measurements 
First stock solutions of tau peptides (1 mM) and GAGs (1 mM) were prepared by 
dissolving in deionized water. ThS was freshly prepared at a concentration of 0.5 mg/ml 
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in 20 mM MOPS buffer, pH 7.  For the ThS measurement, 10 μl of peptide was dissolved 
in 2.5 μl GAG stock solution, 10 μl ThS, and MOPS buffer to make the final 100 μl 
working solution. In the case of RNA, 0.25 ng/ ml, and 0.5 ng/ml of final RNA 
concentrations was used with 100 μM of final tau peptide concentrations. A M3 
spectramax spectrophotometer was used to measure the ThS fluorescence at 440/490 nm, 
excitation and emission. Aggregation kinetic measurements were performed every two 
minutes for 30 minutes, in 96 black well plates. At least three independent experiments 
were carried out and the average readings were obtained.  
 
DLS 
A Malvern zetasizer instrument in the lab was used to measure the size of the aggregation 
of the peptides with GAGs. Samples were prepared under similar conditions used for the 
ThS measurements, but without the ThS, and the size measurements were performed. 
Three independent size measurement experiments were performed for each GAGs 
conditions.   
 
Turbidity measurements 
The peptides aggregation was measured by the turbidity of the samples at 400 nm. 
Samples were prepared under similar conditions used for the ThS study, but  without the 
ThS, and the turbidity measurements were performed using a spectramax M3 
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spectrophotometer in the lab. Three independent size measurement experiments were 




TEM images were obtained using the JEOL JSM 1400 TEM at UM-Ann arbor electron 
microscope facility.  The peptides were aggregated with GAGs for 1 hour, spotted on 
holy carbon copper grids, and then stained with 1% uranyl formate.  
 
 
Cell toxicity assay 
The toxicity of tau peptides aggregates with GAGs on human neuroblastoma SH-SY5Y 
cells was studied by the XTT assay. Cells were obtained from American Type Culture 
Collection (ATCC), and cultured according to the protocol. For the study, 2 x 104 
cells/well, were cultured in 96 well plates over night. Peptides (32 μM) with or without 
GAGs of concentrations (8 μM) were aggregated for 24 hours, and subsequently 
incubated for 48 hours. For RNA induced toxicity, peptides (16 μM) with or without 
RNA of 0.8 ng/ml, was used. XTT assay was measured at 470 nm, and the viability was 
determined according to manufacturer’s protocol.  
 
This article is protected by copyright. All rights reserved.
GAGs surface coating and aggregation assays 
To study the influence of surface coated GAGs on peptide aggregation, first GAGS were 
coated on GAGs binding plates. For GAGs binding, 100 µl solution of 0.01 M PBS 
containing 25 µM of GAGs (Hep, CS, DS, HepS, and HA) were added to a GAGs 
binding plate (Heparin/GAG binding plates (SKU : H/G plates),   and incubated at room 
temperature according to manufacturer’s protocol. After 24 hours, the PBS/GAGs 
solution was aspirated and the wells were washed three times with PBS buffer. For 
aggregation studies on GAGs coated plates, 15 µl of 1 mM Tau N, 15 µl ThS (0.5mg/ml), 
and 120 µl MOPS (20 mM) solution was added into each well. The turbidity of the 
peptide aggregates was measured at 400 nm wavelength after 30 min incubation. The 
morphology of the aggregation was characterized by AFM.  
 
RNA Extraction 
Human brain microvascular endothelial cells (hBMVEC) were cultured at a density of ≤ 
5 x 106 cells/ml. PureLink RNA mini kit was used to extract the RNA from the cells, 
according to the manufacturer’s protocol. Using the Spectra-Drop protocol in spectramax 
M3 spectrophotometer, the absorbance was measured from 230 nm- 280 nm. Then, using 
the measured optical density (OD) at 260 nm and the provided standard curve (OD 260 
nm vs. concentration), the concentration of RNA was obtained. The purified RNA was 
stored at -80°C until used for the aggregation studies.  
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 AFM 
Hitachi AFM 5100N was used to obtain the AFM images for tau peptides samples with 
GAGs and RNA. For preparation, 2 µl of the aggregated sample solutions were spotted 
on freshly cleaved mica, and kept to dry, and washed it with water to remove salt, and 
dried again before imaging. AFM tips (Applied Nanostructures Inc.) with an average 
resonance frequency of 300 kHz, was used to image samples using tapping mode. The 
length and the width of the cantilever are 125 µm and 30 µm respectively, and the 
average force constant is 37 N/m. 
 
Statistical Analysis 
Each experiments were conducted three or more times, and they are presented as mean 
± standard error of the mean (SEM). P-values were determined from the results of at 
least 3-independent experiments. For statistical significance unpaired t-test was used. 
Each GAGs conditions were compared to the controls without GAGs. **p< 0.01, *p< 0.05 
are considered as significance.   
 
3. Results and Discussion 
The goal of the study is to test the influence of polyanions on tau peptides aggregation, 
subsequent fibril formation, and cellular toxicity. For the GAGS induced aggregation 
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study, peptides to GAGs molar ratios of 4:1 or 20:1 were used, at a constant tau peptide 
concentrations of 100 μM. The starting molar ratio 4:1 and tau concentration (100 μM) 
were chosen as previously reported [24, 25], while the 20:1 molar ratio was tested to see 
if the tau peptide: GAGs concentration ratio has an effect on the aggregation. Thioflavin 
S measurements show that the GAGs influence both Tau V, and Tau N peptides 
aggregation in vitro. The enhanced ThS signal in the presence of GAGs may be due to 
the presence of aggregates amount or due to the differences in aggregates structure.  
Increased thioflavin signal of the peptides was observed in the presence of chondroitin 
sulfate, heparin, and dermatan sulfate (Figure 1A, B). Heparan sulfate and hylaluronan on 
the other hand exhibited minimal thioflavin S fluorescence. At both 4:1, and 20:1 molar 
ratios, chondroitin sulfate seems to exhibit enhanced thioflavin S binding of Tau V 
peptide (Figure 1A, Figure S1A). Tau N ThS binding is enhanced in the presence of 
chondroitin sulfate at lower GAG molar ratios (20:1) (Figure S1B), while at higher GAG 
molar ratios (4:1), heparin seems to have more influence on the thioflavin S binding 
(Figure 1B). This may be due to the influence of heparin concentration on tau interaction 
whereas chondroitin sulfate does not seems to influence aggregation at higher molar 
ratio. Also it is important to note that, heparin exhibited significant aggregation (p-value 
< 0.01) compared to the sulfated form of heparin revealed by t-test for the measurements 
(heparin vs heparin sulfate) performed for the ThS the kinetics.  
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DLS, and turbidity measurements were then used to measure the size distribution, and 
turbidity of the peptide aggregates, with and without GAGs. As can be seen from Figure 
2A, chondroitin sulfate, heparin, and dermatan sulfate treated Tau N peptides, exhibited 
larger sizes, indicating the influence on aggregation or fibrillar structures, however 
significance increase in size was observed with chondroitin sulfate treated samples only. 
Similarly, as for the Tau V peptide aggregation size, although increase in the size for all 
the GAGs treated peptides was observed compared to Tau V peptide alone, chondroitin 
sulfate treated peptide samples exhibited significant increase in aggregation size (Figure 
2B). It is also important to point out that the DLS measurements may be influenced by 
the conformational heterogeneity and the size of the aggregates, and hence is an 
approximate method to predict the aggregates size. The turbidity measurements reveal 
significant turbidity with chondroitin sulfate, heparin, heparan sulfate, and dermatan 
sulfate treated peptides compared to Tau V and Tau N peptides alone (Figure 3). 
Hyaluronic acid on the other hand, exhibited no significant turbidity with both peptides. 
However, DLS measurements revealed that TauV samples treated with hyaluronic acid 
showed larger size aggregates (Figure 2B), this may be due to the formation of few 
globular aggregates, which may have contributed to larger size, but not significant 
turbidity.  
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Next we tested the morphology of the Tau N and TauV aggregates by TEM (Figure 4, 5). 
Images reveal, that the Tau N peptides treated with heparin, and chondroitin sulfate 
exhibited significant amount of fibril like structures (Figure 4), in agreement with the 
ThS measurements. Dermatan sulfate treated peptides exhibited aggregates like 
morphology. Also in agreement with the ThS measurements, the TEM images of heparan 
sulfate, and hyaluronic acid treated samples showed no significant aggregation compared 
to other GAGs treated samples. Similar observations were found with Tau V aggregated 
samples (Figure 5), although the amount of aggregation/fibrillar morphology seems to be 
less compared to Tau N aggregates. This is in agreement with ThS measurement, where 
higher fluorescence intensities were observed with Tau N samples compared to Tau V 
samples.  
 
Next we tested whether aggregation or fibrillar morphologies were observed under 
extracellular mimetic conditions of GAGSs. For this, GAGs were coated on special 
GAGs binding plates, and then Tau N peptides solutions were subsequently incubated on 
the surface to allow aggregation. As can be seen from AFM images in Figure S2 A, all 
the GAGs exposed peptides showed aggregates like morphology. However, the amount 
of aggregates seems to be not significant among the GAGS treated and non-treated 
samples. To further confirm this, we did turbidity measurements. TauN peptide buffer 
solutions were incubated on GAGs coated plates and allowed to aggregate. After 30 
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minutes, the supernatant of the samples were taken and turbidity measurements were 
performed. As can be seen from the turbidity study shown in Figure S2 B, there is no 
significant difference among different GAGS treatment compared to untreated GAGs. 
However, among the GAGs, chondroitin sulfate treated samples exhibited more 
aggregation/fibril formation, revealed from both AFM and turbidity. Overall, the data 
suggests, that the intracellular GAGs may have major role in tau aggregation compared to 
extracellular GAGs.  
 
To assess the toxicity effects of GAGs on tau peptide aggregation, we performed cellular 
toxicity studies of Tau N and Tau V aggregated samples in the presence of GAGs. For 
the study, we used SH-SY5Y human neuroblastoma cells, that is widely used as a model 
cell line in neurodegenerative disease studies to assess the toxicity effects [26].  Cells 
were cultured in 96 well plates and incubated with Tau peptides and GAGs solution for 
48 hours and XTT assay was performed to assess the cell viability. As can be seen from 
the Figure 6, all the samples treated with GAGs in solution exhibited toxicity effects. 
While dermatan sulfate treated samples showed a slight increase in toxicity, statistically it 
is not significantly different from other GAGs treated samples. The enhanced toxicity in 
the presence of dermatan sulfate may be due to its influence on the formation of tau 
peptides aggregates like morphology, compared to fibrillar structures as observed from 
the TEM and AFM images. In addition, the peptides alone also show some toxicity 
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effects, may be due to the influence of extracellular GAGs, deposited by the cells. To 
confirm the toxicity effects are due to the peptides aggregation and not due to the GAGs 
itself, we performed the toxicity studies with GAGs only. GAGs alone in solution 
exhibited no significant toxicity (Figure S3). Polyanions including heparin have shown to 
promote tau and tau peptide aggregation by binding to the microtubule hexapeptide 
regions and with the positively charged lysine and histidine aminoacid chains [12]. 
GAGs, which are polyanionic, seem to promote tau aggregation in a similar manner, and 
subsequently exhibit toxic effects on the cells. 
 
 
As a next step, we tested the role of cellular RNA on Tau N and Tau V peptides 
aggregation. For the study we used 0.25, and 0.5 ng/ml of cellular RNA with 100 μM of 
peptide final concentrations. Both peptides showed enhanced aggregation in the presence 
of RNA, observed from increase in ThS fluorescence (Figure 7A, B). To determine 
whether it has similar aggregation kinetics like GAGs, we calculated the rate constants of 
TauN and Tau V in the presence of chondroitin sulfate, heparin, and RNA. The ThS 
curves were fitted using four-parameter sigmoidal curve using Matlab with the following 
equation 𝑦 = 𝑦𝑜 + 𝑎
1+𝑒−(𝑥−𝑥𝑜)/𝑏  , here 𝑦𝑜 - initial ThS fluorescence, xo- 50% of the 
maximum fluorescence value, a-maximal fluorescence value, y and x are the ThS 
fluorescence, and time, as previously reported in literature to determine protein 
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aggregation kinetics [27]. As can be seen from Table 1, the RNA and GAGs influence on 
the aggregation kinetics is comparable within the peptides. However, Tau V in the 
presence of GAGs and RNA showed faster kinetics compared to Tau N samples. This is 
further evidenced by AFM imaging where Tau V treated with RNA exhibited more 
aggregates compared to Tau N in general (Figure 7C). From the images, Tau N seems to 
drive more fibril like structures, while Tau V forms more globular aggregates.  Finally, 
the RNA mediated Tau V and Tau N aggregates toxicity was assessed in SH-SY5Y cells. 
Tau V exhibited significant toxicity, whereas Tau N did not exhibit toxicity at the tested 
concentrations (Figure 8). This may be due to the significant Tau V aggregation 
formation in the presence of RNA (Figure 7).  
 
Glycosaminoglycans have shown to play a key role in Alzheimer’s disease. A recent 
study reveal that increase evidence suggest that N-glycans may play an important role in 
Alzheimer’s disease [28]. In another study, it is stated that GAGs have a scaffolding role 
on amyloidogenic proteins [29]. Further, it has been reported that glycosaminoglycan 
heparin, which is anionic in nature, believed to play a key role in the tau aggregation by 
interacting with the microtubule binding region [13, 18]. RNA also known to play a key 
role in tau aggregation. Kampers et. al has shown that in the presence bovine or yeast 
RNA, the tau was assembled into paired helical filaments [14]. Here we show that 
GAGS, and human brain endothelial cellular RNA in solution have the capability to 
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influence the tau peptides aggregation, fibrillization and toxicity in vitro. As far as GAGs 
are concerned, chondroitin sulfate, dermatan sulfate, and heparin seem to influence the 
peptide aggregation more compared to other GAGs. Although it has been reported that 
the sulfated form of heparin is found in the amyloid plaques, it did not promote 
significant aggregation of tau peptides under in vitro conditions. Hyaluronic acid showed 
the least aggregation promoting effects among the GAGs studied. Further, the GAGs in 
solution seems to have more influence on the aggregation compared to the surface coated 
GAGs. Cellular RNA in few ng/ml concentrations on the hand, exhibited significant 
aggregation and toxicity of Tau V peptides that is known to be a key driver in tau 




From this proof of concept study, we show that the polyanions influence the microtuble 
tau peptide, and mutant peptide aggregation under in vitro conditions. The kind of 
glycosaminoglycan, and the sulfate modifications, and the physical representation also 
seems to influence the aggregation mechanism. The studies also show, cellular RNA may 
to play a significant role in tau aggregation and toxicity. This study could open further 
opportunities for the investigation of polyanions associated tau aggregation mechanisms 
and therapeutic interventions.  
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Figure Legends 
Figure 1. A). Tau V peptide (100 μM) aggregation kinetics was studied with GAGs (25 
μM). B). Tau N peptide (100 μM) aggregation kinetics was studied with GAGs (25 μM). 
ThS fluorescence, show the aggregation is influenced by the presence of 
glycosaminoglycan used.  Experiments were repeated three times (n= 3), and averaged. 
Here Tau V- VQIVYK; TauN- GKVQIINKLDL; CS-chondroitin sulfate; Hep-heparin; DS-
Dermatan sulfate; HepS- heparan sulfate; HA-hyaluronic acid; ThS-thioflavin S.  
 
 
Figure 2A. (i). Dynamic light scattering measurements of the Tau N peptide (100 μM) 
aggregates with GAGs (25 μM). ii) Tau V peptide (100 μM) aggregation with and without 
GAGs (25 μM), assessed by turbidity measurements. The average sizes of each peptide 
with and without GAGs are tabulated on the right for three experiments. * p < 0.05. Data 
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are expressed as mean ± SEM. 
 
 
Figure 3. (i). Turbidity measurements of the Tau N peptide (100 μM) aggregates with 
GAGs (25 μM). (ii) Tau V peptide (100 μM) aggregation with and without GAGs (25 μM), 
assessed by turbidity measurements. * p < 0.05. Experiments were performed in 
triplicates and data are expressed as mean ± SEM. 
 
 
Figure 4. TEM images of Tau N (100 μM) peptide aggregation in the presence of GAGs 
(25 μM). The aggregates were made in MOPS buffer at 37°C, and the samples were 
spotted on holy carbon grids, and negatively stained with 1% uranyl formate prior to 
imaging. Scale bar 1 μm. 
 
Figure 5. TEM images of Tau V (100 μM) peptide aggregation in the presence of GAGs 
(25 μM). The samples were aggregated in MOPS buffer at 37°C, and TEM images were 
obtained to assess the morphology using the similar procedure used for Tau N samples. 
Scale bar 1 μm. 
 
Figure 6. Toxicity effect of Tau peptides aggregates with GAGs on SH-SY5Y cells. A) 
Tau N with GAGs B) Tau V with GAGs. * p < 0.05. Data are expressed as mean ± SEM, 
for three experiments. 
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 Figure 7. (A). Tau N peptide (100 μM) aggregation kinetics was studied with RNA 
concentrations of 0.25ng/ ml and 0.5ng/ml. (B). Tau V peptide (100 μM) aggregation 
kinetics was studied with RNA concentrations of 0.25ng/ ml and 0.5 ng/ml. ThS 
fluorescence, reveal the Tau V aggregation is significantly influenced by the presence of 
RNA.  (C). AFM images of Tau N and Tau V peptide aggregation in the presence of 
RNA. 
 
Figure 8. Toxicity effect of Tau peptides aggregates in the presence of RNA on SH-
SY5Y cells. Tau N and Tau V at 16 μM concentrations were incubated with and without 
0.8 ng/ml RNA, and toxicity was performed after 48 hours. *p< 0.05 indicate 
significance, determined from three independent experiments, and data are expressed 




Table 1: Apparent rate constant of tau peptides aggregation with GAGs and RNA 
 
Note: Here Tau V-100 μM; CS, Hep - 25 μM; RNA-0.5 ng/ml. Tau V and Tau N alone 
exhibited negligible Kapp values, indicting very slow kinetics in the absence of GAGs or 
RNA, and hence not reported in the table.  
Kapp (min-1) 
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